tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'Bristol-Myers Squibb'

Chicago Investment Firm Assumes $27 Million Risk to Help Nuvilex Unseat Celgene and Eli Lilly

Chicago Investment Firm Assumes $27 Million Risk to Help Nuvilex Unseat Celgene and Eli Lilly

Written by ι Stock Market Media Group Staff — February 24, 2014

Lincoln Park Capital (LPC) purchased 8 million restricted shares of Nuvilex, Inc. (OTCQB: NVLX) in exchange for an initial $2 million out of what can be viewed as a $27 million “pot of money” to advance the company’s late-phase pancreatic cancer clinical trials.  Notice we said restricted shares, that’s right, LPC has put a great deal of its money on the line with a number of built in protections for Nuvilex.  ...

Read More →
0

Move over Celgene Here Comes Nuvilex and $27 Million to Advance Its Pancreatic Cancer Clinical Trials

Move over Celgene Here Comes Nuvilex and $27 Million to Advance Its Pancreatic Cancer Clinical Trials

Written by ι Stock Market Media Group Staff — February 21, 2014

Nuvilex, Inc. (OTCQB: NVLX) just became relevant in the biotech industry.  The company can now move forward with its clinical trials for the treatment of advanced inoperable pancreatic cancer after Nuvilex landed a $27 million funding deal that could change the sector for years to come.  Funding is always the biggest hurdle for any small biotechnology or pharmaceutical firm, and its why larger firms with competing treatments can often sit back ...

Read More →
0

Nuvilex’s Pancreatic Cancer Treatment Readies to Challenge Eli Lilly and Celgene in Late-Phase Clinical Trials

Nuvilex’s Pancreatic Cancer Treatment Readies to Challenge Eli Lilly and Celgene in Late-Phase Clinical Trials

Written by ι Stock Market Media Group Staff — February 19, 2014

Nuvilex, Inc. (OTCQB: NVLX) is a small biotech firm in Silver Spring, Maryland, that hopes to soon be mentioned with much larger biotechnology and pharmaceutical companies like Eli Lilly and Celgene. If the company’s pancreatic cancer treatment that combines the proprietary cellulose-based live-cell encapsulation technology known as Cell-in-a-Box™ with the anti-cancer drug ifosfamide can produce the same or better data in its upcoming late-phase clinical trials in advanced, inoperable pancreatic cancer than ...

Read More →
0

Nuvilex, Inc. Enters Most Important Step of Phase III Trials Outside of Patient Enrollment

Nuvilex, Inc. Enters Most Important Step of Phase III Trials Outside of Patient Enrollment

Written by ι Stock Market Media Group Staff — October 1, 2013

When Nuvilex, Inc. (OTCQB: NVLX) announced that it had contracted Inno Biologics to generate cell clones that will be the basis of the company’s future Phase III clinical trials in advanced, inoperable, pancreatic cancer, many investors may not have realized this is the most vital step in the process of beginning the company’s future late-stage clinical trials next to the actual enrollment of patients.  Nuvilex’s success in its future trials, and ...

Read More →
0

FDA Approves ABRAXANE® for Pancreatic Cancer, Could Nuvilex’s Treatment Be Next

FDA Approves ABRAXANE® for Pancreatic Cancer, Could Nuvilex’s Treatment Be Next

Written by ι Stock Market Media Group Staff — September 9, 2013

After presenting the results of its large scale Phase III clinical trial at the 2013 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in late January, the U.S. Food and Drug Administration (FDA) moved quickly to approve Celgene Corp.’s (NASDAQ: CELG) ABRAXANE® when used in combination with gemcitabine. Celgene announced late last Friday that the FDA has approved its supplemental new drug application of the combination as first-line treatment ...

Read More →
0

Drug Makers Could Soon Turn Away From Eli Lilly’s Gemzar and Toward Nuvilex’s Cell Encapsulation

Drug Makers Could Soon Turn Away From Eli Lilly’s Gemzar and Toward Nuvilex’s Cell Encapsulation

Written by ι Stock Market Media Group Staff — August 22, 2013

While Eli Lilly’s (NYSE: LLY) cancer fighting drug Gemzar (gemcitabine) has been on the market since the late 1990s, its success with cancer duly noted, other big pharmaceutical companies are combining their own drugs with  gemcitabine in their own clinical trials in an attempt to improve upon the gemcitabine’s effectiveness when that drug is used alone for the treatment of advanced, inoperable pancreatic cancer, but they’re not finding much success.  ...

Read More →
0
Page 1 of 2 12
ContactUs.com